Abstract
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan
hydrochloride in treating younger patients with solid tumors that have come back (relapsed)
or that have not responded to standard therapy (refractory). Adavosertib and irinotecan
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
